ADVERTISEMENT
Biocon Gets USFDA Nod For Generic Anti-Cancer Drug
The approval will further strengthen the company's portfolio of vertically integrated, complex drug products, the company said.
06 Feb 2024, 08:39 PM IST 
Save
(Source: Biocon website)
Show Quick Read
Summary is AI Generated. Newsroom Reviewed
Biocon Ltd. on Tuesday said it has received approval from the U.S. health regulator for a generic anti-cancer medication.
The company has received approval from the U.S. Food and Drug Administration for Dasatinib tablets to market in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, Biocon said in a regulatory filing.
The approval will further strengthen the company's portfolio of vertically integrated, complex drug products, it added.
Shares of Biocon settled 4.97% higher at Rs 298.75 apiece on the BSE.
